jackie.vuistiner

Quotidiano Nazionale: a technology that saves lives

The article from Italy’s Quotidiano Nazionale features an interview with our CEO and co-founder Daniela Marino. She discusses our pioneering work in creating bioengineered skin on demand. Daniela highlights the benefits of this technology and our approach which allows us to generate large amounts of skin from a small patient’s own skin sample. More than […]

Quotidiano Nazionale: a technology that saves lives Read More »

CUTISS announces first closing of CHF 25M in Series C funding round

Switzerland, 17 May 2024 – CUTISS AG, a Swiss pioneering life sciences company specializing in skin regenerative medicine and tissue engineering, is glad to announce the first closing of CHF 25 million in its Series C funding round. This milestone demonstrates strong investor confidence in CUTISS’ mission and progress to transform skin surgery. The Series

CUTISS announces first closing of CHF 25M in Series C funding round Read More »

Tech.eu: life changing hope for burn victims

Tech.eu, the premier online publication dedicated to the growing European technology ecosystem, writes about CUTISS’s breakthrough with denovoSkin, a bioengineered skin graft designed to grow with patients, improving quality of life and significantly reducing the need for follow-up surgeries. The innovative skin graft is derived from a small piece of the patient’s healthy skin and

Tech.eu: life changing hope for burn victims Read More »

CUTISS continues collaboration with Santobono Hospital in Naples to transform pediatric burn care

A significant milestone in pediatric burn care in Italy has been achieved with the inauguration of the new pediatric burn center at Santobono Hospital in Naples, a new center of excellence at European level. Since 2021, Santobono has been the coordinating center in Italy for our Phase 2 clinical trial of denovoSkin™, the bioengineered autologous

CUTISS continues collaboration with Santobono Hospital in Naples to transform pediatric burn care Read More »

Positive one-year follow-up data from Phase 2 trial of denovoSkin™

Switzerland, 14 February 2024 – CUTISS AG, a Swiss clinical-stage life science company focused on skin regenerative medicine and tissue engineering, has announced positive one-year follow-up data from its Phase 2 clinical trial of the lead product denovoSkin™, in adult and adolescent severe burn patients. Following the announced positive primary endpoint in Q1 2023, the one-year readout

Positive one-year follow-up data from Phase 2 trial of denovoSkin™ Read More »

TeleZüri features CUTISS’s denovoSkin™: Advancing Burn Treatment

Discover CUTISS’s strides in developing the personalized skin tissue therapy denovoSkin™, as seen on TeleZüri’s CheckUp. The segment shares a patient’s remarkable recovery story, demonstrates how our pioneering skin graft technology can positively impact patients’ lives, and includes insights from CEO Dr. Daniela Marino. Watch the reportage to see the significant advancements denovoSkin™ brings to

TeleZüri features CUTISS’s denovoSkin™: Advancing Burn Treatment Read More »

Interview about denovoSkin™ in Superinteressante

The popular and influential Brazilian science magazine Superinteressante interviewed our CEO Daniela Marino about our development of denovoSkin™. The article describes the ways in which denovoSkin™ could revolutionize skin surgery and benefit patients worldwide. “We’re moving towards the last stage of development, and we hope to bring the technology to patients soon,” said Daniela in

Interview about denovoSkin™ in Superinteressante Read More »

Recruitment completed for denovoSkin™ Phase 2 clinical trial in reconstructive surgery

Switzerland, 07 November – CUTISS AG, a Swiss clinical-stage life sciences company focused on skin regenerative medicine and tissue engineering, has announced the successful completion of patient recruitment for the Phase 2 clinical trial of its lead product, denovoSkin™, in reconstructive surgery for both children and adults. This Phase 2 clinical trial evaluates the safety

Recruitment completed for denovoSkin™ Phase 2 clinical trial in reconstructive surgery Read More »

Scroll to Top

Newsletter

Would you like to contact us as a journalist?

©WyssZurich

This website uses cookies to ensure you get the best experience on our website.